X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (929) 929
male (718) 718
pharmacology & pharmacy (592) 592
anti-ulcer agents - pharmacokinetics (581) 581
adult (461) 461
female (431) 431
anti-ulcer agents - pharmacology (395) 395
anti-ulcer agents - administration & dosage (382) 382
omeprazole (374) 374
pharmacokinetics (360) 360
anti-ulcer agents - therapeutic use (352) 352
proton pump inhibitors (325) 325
animals (294) 294
index medicus (266) 266
lansoprazole (253) 253
omeprazole - pharmacokinetics (249) 249
2-pyridinylmethylsulfinylbenzimidazoles (238) 238
middle aged (232) 232
administration, oral (227) 227
omeprazole - analogs & derivatives (225) 225
drug interactions (224) 224
gastroenterology & hepatology (218) 218
cross-over studies (208) 208
area under curve (207) 207
anti-ulcer agents - blood (181) 181
rats (181) 181
anti-ulcer agents - adverse effects (162) 162
omeprazole - administration & dosage (161) 161
omeprazole - pharmacology (158) 158
biological availability (137) 137
aged (136) 136
gastroesophageal reflux - drug therapy (127) 127
omeprazole - therapeutic use (126) 126
pantoprazole (115) 115
cytochrome p-450 cyp2c19 (109) 109
hydrogen-ion concentration (109) 109
adolescent (108) 108
half-life (108) 108
chromatography, high pressure liquid (106) 106
proton pump inhibitor (105) 105
dose-response relationship, drug (104) 104
rabeprazole (101) 101
treatment outcome (101) 101
helicobacter infections - drug therapy (98) 98
double-blind method (95) 95
time factors (94) 94
metabolism (92) 92
omeprazole - blood (92) 92
peptic ulcer - drug therapy (89) 89
helicobacter pylori (88) 88
genotype (84) 84
esomeprazole (80) 80
ranitidine (80) 80
anti-ulcer agents - metabolism (78) 78
gastric acid - secretion (78) 78
anti-ulcer agents - chemistry (76) 76
aryl hydrocarbon hydroxylases - genetics (75) 75
pharmacology/toxicology (75) 75
bioavailability (72) 72
drug therapy, combination (72) 72
gastric acidity determination (72) 72
intragastric ph (72) 72
pharmacology (72) 72
stomach ulcer - drug therapy (71) 71
gastroesophageal-reflux disease (68) 68
absorption (67) 67
omeprazole - adverse effects (67) 67
analysis (66) 66
benzimidazoles - pharmacology (66) 66
benzimidazoles - pharmacokinetics (65) 65
gastric mucosa - drug effects (65) 65
therapy (64) 64
young adult (63) 63
medicine & public health (62) 62
toxicology (62) 62
mixed function oxygenases - genetics (61) 61
drug administration schedule (60) 60
gastric acid - metabolism (60) 60
rats, sprague-dawley (60) 60
cyp2c19 (59) 59
efficacy (59) 59
helicobacter-pylori infection (58) 58
gastroesophageal reflux disease (57) 57
pharmacodynamics (56) 56
rats, wistar (56) 56
gastroesophageal reflux (55) 55
benzimidazoles - therapeutic use (54) 54
gastric mucosa - metabolism (54) 54
cimetidine (53) 53
2-pyridinylmethylsulfinylbenzimidazoles - pharmacokinetics (52) 52
double-blind (52) 52
management (52) 52
enzyme inhibitors - pharmacokinetics (50) 50
ulcers (49) 49
drug therapy (48) 48
enzyme inhibitors - pharmacology (48) 48
ranitidine - pharmacokinetics (48) 48
duodenal ulcer - drug therapy (47) 47
injections, intravenous (47) 47
child (46) 46
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1118) 1118
Japanese (16) 16
German (13) 13
Russian (10) 10
French (6) 6
Chinese (5) 5
Spanish (5) 5
Hungarian (2) 2
Italian (2) 2
Polish (2) 2
Danish (1) 1
Dutch (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 03/2009, Volume 53, Issue 3, pp. 958 - 966
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit... 
CELL TRANSPLANT RECIPIENTS | STEADY-STATE PHARMACOKINETICS | BEVERAGE COCA-COLA | SALVAGE THERAPY | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | FOOD INTERACTION | INVASIVE FUNGAL-INFECTION | ITRACONAZOLE | TRIAZOLE ANTIFUNGAL | VERSUS-HOST-DISEASE | FLUCONAZOLE | Triazoles - administration & dosage | Triazoles - adverse effects | Antifungal Agents - adverse effects | Triazoles - blood | Area Under Curve | Humans | Middle Aged | Omeprazole - blood | Intestinal Absorption - drug effects | Male | Anti-Ulcer Agents - blood | Gastric Mucosa - metabolism | Anti-Ulcer Agents - pharmacokinetics | Dose-Response Relationship, Drug | Young Adult | Antifungal Agents - pharmacokinetics | Hydrogen-Ion Concentration - drug effects | Gastric Mucosa - drug effects | Adult | Female | Triazoles - pharmacokinetics | Suspensions | Eating | European Continental Ancestry Group - genetics | Fasting | Drug Administration Schedule | Administration, Oral | Food-Drug Interactions | Omeprazole - administration & dosage | Anti-Ulcer Agents - adverse effects | African Americans - genetics | European Continental Ancestry Group - statistics & numerical data | Omeprazole - adverse effects | Omeprazole - pharmacokinetics | Carbonated Beverages | Anti-Ulcer Agents - administration & dosage | Cross-Over Studies | African Americans - statistics & numerical data | Antifungal Agents - administration & dosage | Antifungal Agents - blood | Index Medicus | Pharmacology
Journal Article
Annals of Surgery, ISSN 0003-4932, 08/2013, Volume 258, Issue 2, pp. 262 - 269
OBJECTIVE:We conducted a pharmacokinetic (PK) study and a pharmacodynamic (PD) study to assess whether Roux-en-Y gastric bypass (RYGB) surgery is associated... 
furosemide | oral cocktail | CYP3A | gastric bypass | drug metabolism | SURGERY | FATTY LIVER-DISEASE | WEIGHT-LOSS | TRENDS | P-GLYCOPROTEIN | OBESITY | INTESTINAL ADAPTATION | BARIATRIC SURGERY | ABSORPTION | HEPATIC STEATOSIS | Gastric Bypass | Diuretics - pharmacokinetics | Excitatory Amino Acid Antagonists - pharmacokinetics | Humans | Middle Aged | Tolbutamide - urine | Male | Caffeine - pharmacokinetics | Midazolam - urine | Anti-Ulcer Agents - pharmacokinetics | Young Adult | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Diuretics - urine | Diuretics - administration & dosage | Hypoglycemic Agents - pharmacokinetics | Administration, Oral | Furosemide - pharmacokinetics | Omeprazole - administration & dosage | Excitatory Amino Acid Antagonists - administration & dosage | Hypoglycemic Agents - urine | Omeprazole - urine | Central Nervous System Stimulants - pharmacokinetics | Midazolam - blood | Dextromethorphan - urine | Adolescent | GABA Modulators - urine | Central Nervous System Stimulants - urine | Dextromethorphan - administration & dosage | Furosemide - administration & dosage | Tolbutamide - administration & dosage | Tolbutamide - pharmacokinetics | Caffeine - administration & dosage | Omeprazole - blood | GABA Modulators - pharmacokinetics | Midazolam - administration & dosage | Anti-Ulcer Agents - blood | Chromatography, High Pressure Liquid | Case-Control Studies | Excitatory Amino Acid Antagonists - urine | Hypoglycemic Agents - blood | Tandem Mass Spectrometry | Biotransformation | Adult | Female | Dextromethorphan - pharmacokinetics | Furosemide - urine | Caffeine - urine | Caffeine - blood | GABA Modulators - administration & dosage | GABA Modulators - blood | Omeprazole - pharmacokinetics | Anti-Ulcer Agents - urine | Midazolam - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Dextromethorphan - blood | Excitatory Amino Acid Antagonists - blood | Tolbutamide - blood | Aged | Central Nervous System Stimulants - blood | Pharmacokinetics | Central Nervous System Stimulants - administration & dosage
Journal Article
British Journal of Clinical Pharmacology, ISSN 0306-5251, 12/2009, Volume 68, Issue 6, pp. 928 - 935
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Numerous cocktails using concurrent administration of several cytochrome P450 (CYP) isoform-selective probe drugs... 
in vivo drug-drug interaction | cocktail | CYP | Cocktail | In vivo drug-drug interaction | DRUG | CAFFEINE | COMBINED PHENOTYPIC ASSESSMENT | METOPROLOL | OMEPRAZOLE TREATMENT | XANTHINE-OXIDASE | METABOLISM | ENZYMES | IN-VIVO | N-ACETYLTRANSFERASE-2 | PHARMACOLOGY & PHARMACY | Anti-Anxiety Agents - administration & dosage | Caffeine - administration & dosage | Anticoagulants - administration & dosage | Area Under Curve | Humans | Midazolam - administration & dosage | Cytochrome P-450 CYP1A2 - administration & dosage | Male | Metabolic Clearance Rate | Warfarin - administration & dosage | Caffeine - pharmacokinetics | Anti-Ulcer Agents - pharmacokinetics | Young Adult | Anti-Anxiety Agents - pharmacokinetics | Drug Interactions | Adult | Drug Therapy, Combination | Administration, Oral | Omeprazole - administration & dosage | Omeprazole - pharmacokinetics | Midazolam - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Central Nervous System Stimulants - pharmacokinetics | Anticoagulants - pharmacokinetics | Central Nervous System Stimulants - administration & dosage | Drug Combinations | Cytochrome P-450 CYP1A2 - pharmacokinetics | Omeprazole | Warfarin | Analysis | Drug interactions | Cytochrome P-450 | Physiological aspects | Liquid chromatography | Mass spectrometry | Caffeine | Drug Metabolism | in vivo drug–drug interaction
Journal Article
Journal Article
Molecular Pharmaceutics, ISSN 1543-8384, 01/2012, Volume 9, Issue 1, pp. 14 - 28
As 95% of all prescriptions are for orally administered drugs, the issue of oral absorption is central to the development of pharmaceuticals. Oral absorption... 
ranitidine | mucoadhesion | hydrophobic drugs | griseofulvin | cyclosporin A | idarubicin | chitosan amphiphiles | hydrophilic drugs | transcellular transport | oral absorption | AQUEOUS-SOLUTIONS | PERMEABILITY | VESICLES | MONOLAYERS | P-GLYCOPROTEIN | DELIVERY | IN-VITRO | TRANSPORT | CYCLOSPORINE-A | EPITHELIAL CACO-2 CELLS | PHARMACOLOGY & PHARMACY | Intestinal Mucosa - metabolism | Nanoparticles - chemistry | Rats, Wistar | Ranitidine - pharmacokinetics | Humans | Drug Carriers - administration & dosage | Idarubicin - pharmacokinetics | Male | Drug Carriers - analysis | Anti-Ulcer Agents - blood | Quaternary Ammonium Compounds - chemistry | Griseofulvin - blood | Intestinal Absorption | Anti-Ulcer Agents - pharmacokinetics | Cyclosporine - blood | Intestinal Mucosa - cytology | Griseofulvin - pharmacokinetics | Griseofulvin - metabolism | Antifungal Agents - pharmacokinetics | Antifungal Agents - metabolism | Cyclosporine - pharmacokinetics | Idarubicin - administration & dosage | Antibiotics, Antineoplastic - pharmacokinetics | Chitosan - analogs & derivatives | Cyclosporine - metabolism | Griseofulvin - administration & dosage | Caco-2 Cells | Idarubicin - metabolism | Drug Carriers - metabolism | Adhesiveness | Nanoparticles - ultrastructure | Rats | Anti-Ulcer Agents - administration & dosage | Ranitidine - metabolism | Antibiotics, Antineoplastic - administration & dosage | Animals | Chitosan - chemistry | Ranitidine - blood | Intestine, Small - cytology | Anti-Ulcer Agents - metabolism | Cyclosporine - administration & dosage | Hydrophobic and Hydrophilic Interactions | Drug Carriers - pharmacokinetics | Intestine, Small - metabolism | Ranitidine - administration & dosage | Antibiotics, Antineoplastic - metabolism | Antifungal Agents - administration & dosage | Antifungal Agents - blood
Journal Article
Journal Article
Journal Article
Journal of Clinical Pharmacology, ISSN 0091-2700, 05/2008, Volume 48, Issue 5, pp. 553 - 562
A total of 71 HIV-negative healthy adults were randomized to 1 of 6 regimens to receive lopinavir/ritonavir tablets 400/100 mg twice daily (bid) or 800/200 mg... 
Atazanavir | Pharmacokinetics | Acid-reducing agents | Ritonavir | Lopinavir | acid-reducing agents | lopinavir | EFFICACY | atazanavir | ritonavir | pharmacokinetics | VALIDATION | PHARMACOLOGY & PHARMACY | CLINICAL PHARMACOKINETICS | PROTEASE INHIBITORS | Area Under Curve | Ranitidine - pharmacokinetics | Humans | Middle Aged | Pyridines - pharmacokinetics | Biological Availability | Male | Anti-HIV Agents - administration & dosage | Anti-Ulcer Agents - pharmacokinetics | Dose-Response Relationship, Drug | Histamine H2 Antagonists - administration & dosage | Drug Interactions | HIV Protease Inhibitors - pharmacokinetics | Atazanavir Sulfate | Adult | Female | Ranitidine - adverse effects | Anti-HIV Agents - blood | HIV Protease Inhibitors - blood | Pyridines - administration & dosage | Oligopeptides - blood | Ritonavir - administration & dosage | Ritonavir - blood | Oligopeptides - pharmacokinetics | Omeprazole - administration & dosage | Anti-Ulcer Agents - adverse effects | Histamine H2 Antagonists - adverse effects | Omeprazole - adverse effects | Omeprazole - pharmacokinetics | HIV Protease Inhibitors - administration & dosage | Histamine H2 Antagonists - pharmacokinetics | Anti-Ulcer Agents - administration & dosage | Pyridines - blood | Pyrimidinones - pharmacokinetics | Ritonavir - pharmacokinetics | Pyrimidinones - blood | Anti-HIV Agents - pharmacokinetics | Oligopeptides - administration & dosage | Pyrimidinones - administration & dosage | Ranitidine - administration & dosage | Antiviral agents | Dosage and administration | Research | Drug interactions | Index Medicus
Journal Article
Journal Article
Journal Article
Journal of Veterinary Internal Medicine, ISSN 0891-6640, 03/2019, Volume 33, Issue 2, pp. 531 - 535
Journal Article